Search Results

The PreView PHP™ is intended for use in the detection and monitoring the progression of Agerelated Macular Degeneration (AMD) including, but not limited to, the detection of choroidal neovascularization (CNV).

The PreView Preferential Hyperacuity Perimeter (PreView PHP™) is intended for use in The detection and characterization of central and paracentral metamorphopsia (visual distortion) in patients with age-related macular degeneration , as an aid in monitoring progression of disease factors causing metamorphopsia including but not limited to progression of assouse ration (CNV). It is intended to be used in the office of a licensed eye care practitioner in patients with stable fixation.

The PreView PHP™ system is an interactive software driven device that provides a series of horizontal and vertical linear images to the macular region of the eye to detect abnormalities of the central and paracentral visual field that will detect and monitor progression of age related macular degeneration including detection of choroidal neovascularization. The changes in macular and near macular function are identified by the device thus enabling the reader to detect intermediate and advancing changes in macular degeneration and associated diseases to provide the capability for earlier intervention.

The PreView PHP™ is a specialized perimeter, and applies the concept of the static and automated permeter in the detection of visual field defects. The device incorporates the theory of hyperacuity to address more highly specific central and paracentral visual fields. Because of hyperacuity, perception of more finite relative spatial localization. Hyperacuity is defined as the ability to perceive a difference in the relative spatial localization of points on the central field, more specific distortions or misalignments within the central and paracentral field can be mapped with greater accuracy. The device monitors and manages the progressive changes associated with advancing macular degeneration and differentiates the different stages of AMD including but not limited to choroidal neovascularization.

The PreView PHP™ system is designed for use with standard off-the-shelf PC units in the office of the practitioner. It is aimed to detect advancing changes of AMD-related lesions including but not limited to choroidal neovascularlization.

Here's a breakdown of the acceptance criteria and study details for the PreView PHP™ device, based on the provided text:

Acceptance Criteria and Device Performance

Study Details:

1. Sample Size used for the test set and data provenance:

   • The document does not explicitly state the sample size of the test set patients. However, it does mention that the study was a "prospective, comparative, concurrent, non-randomized multicenter study."
   • Data Provenance: The document states the manufacturer is Notal Vision, Inc. from Tel Aviv, Israel, and the clinical investigation was also conducted in Israel. Based on the mention of "multicenter study," it suggests data was collected from multiple sites.

2. Number of experts used to establish the ground truth for the test set and qualifications of those experts:

   • The document does not provide information on the specific number of experts or their qualifications that established the ground truth for the test set.

3. Adjudication method for the test set:

   • The document does not specify an adjudication method.

4. If a multi-reader multi-case (MRMC) comparative effectiveness study was done. If so, what was the effect size of how much human readers improve with AI vs without AI assistance:

   • The provided text does not describe an MRMC comparative effectiveness study where human readers' performance with and without AI assistance was evaluated. The study focused on the standalone performance of the PreView PHP™ device.

5. If a standalone (i.e., algorithm only without human-in-the-loop performance) was done:

   • Yes, a standalone study was done. The clinical investigation assessed the ability of the Preferential Hyperacuity Perimeter (PreView PHP™) itself to detect recent onset of choroidal neovascularization (CNV) and differentiate it from an intermediate stage of AMD. The reported sensitivity and specificity are for the device's performance directly.

6. The type of ground truth used:

   • The ground truth for the test set was based on untreated CNV from AMD diagnosed within the last 60 days or an intermediate stage of AMD (at least 1 large druse or at least 20 medium-size drusen) with no evidence of geographic atrophy or other macular diseases. This implies a clinical diagnosis by ophthalmologists, likely supported by other diagnostic methods (which are not explicitly detailed in the provided text for ground truth establishment, though the referenced predicate devices include technologies like the Heidelberg Retina Angiograph FA/ICGA).

7. The sample size for the training set:

   • The document does not specify a separate training set or its sample size. The clinical investigation appears to be a validation study.

8. How the ground truth for the training set was established:

   • As no separate training set is explicitly mentioned, how its ground truth was established is not provided. The device likely predates or was developed concurrently with modern machine learning paradigms requiring distinct training and test sets in the same way.

Ask a specific question about this device